- Company
- Samsung Bioepis' biosimilar had ₩1.5 trillion
- by Chon, Seung-Hyun Feb 22, 2022 05:54am
- Biosimilar products developed by Samsung Bioepis generated 1.5 trillion won in sales overseas last year. It increased by more than 10% from the previous year, the largest ever. According to Samsung Bioepis on the 18th, five biosimilars recorded a total of $1.255.1 billion (about 1.5 trillion won) in overseas markets last year. It achieved
- Company
- Kymriah is expected to be able to register insurance benefit
- by Eo, Yun-Ho Feb 21, 2022 05:59am
- Kymriah, an ultra-high-priced one-shot treatment, is expected to be covered by insurance benefits as early as April. According to related industries, Novartis Korea's CAR-T new drug Kymriah officially began drug price negotiations with NHIS in the last week of the same month after passing the Drug Benefit Evaluation Committee of the HIRA on J
- Company
- Development of Xolair biosimilars is in full swing
- by Ji Yong Jun Feb 21, 2022 05:58am
- Domestic and foreign bio companies have started to develop Xolair (Omalizumab) biosimilars which patents expire in two years. The development stage of Celltrion, a domestic company, is the fastest. According to Clinical Trials, a clinical registration site of the NIH on the 17th, six clinical trials of Xolair biosimilars are currently registe
- Company
- Vitrakvi's price negotiation has been extended
- by Eo, Yun-Ho Feb 18, 2022 05:55am
- According to related industries, both Roche's Rozlytrek (NTRK) anticancer drugs, Roche Korea's Rozlytrek and Bayer Korea's Vitrakvi, failed to conclude discussions with the NHIS (60 days) in January. The two drugs seeking the PE system passed the HIRA's Drug Benefit Evaluation Committee last year, but are in the final stage. If the extende
- Company
- AstraZeneca wins second trial on ‘Forxiga substance patent'
- by Kim, Jin-Gu Feb 18, 2022 05:55am
- AstraZeneca, the original drug maker of the SGLT-2 inhibitor for the treatment of diabetes, ‘Forxiga,’ won the second trial over its substance patent. The ruling has abruptly put a hold on Dong-A ST’s plans for the early release of its Forxiga latecomer. The industry interpreted this as a crisis for the ‘pro-drug strategy’ that has b
- Company
- The industry is worried about the spread of Omikron
- by Kim, Jin-Gu Feb 18, 2022 05:55am
- The Omicron mutation COVID-19 virus is also hurting factories and research institutes of pharmaceutical bio companies. Concerns are growing over production disruptions as a series of confirmed cases have emerged in Hwaseong Hyangnam Pharmaceutical Industrial Complex and Cheongju Osong Life Science Complex, where pharmaceutical factories are
- Company
- The development of next lung cancer txs is in full swing
- by Feb 17, 2022 05:53am
- Starting with EGFR, treatments have been released. The first dual inhibitor was also released. Non-small cell lung cancer treatment is facing a new turning point with the emergence of various targeted anticancer drugs. Precise treatment began by pioneering areas where there were no treatments, such as KRAS, MET, and EGFR Exon 20. ◆ New
- Company
- Seqirus “to supply next-gen influenza vaccine” in Korea
- by Feb 17, 2022 05:53am
- A new competitor has entered the influenza vaccine market. Seqirus, a subsidiary of the Australia-based biotech firm CSL, will be entering the Korean market in earnest in the COVID-19 pandemic. Seqirus Korea held an online press conference to celebrate the official launch of its Korean subsidiary on the 16th. At the conference, Seqirus th
- Company
- Roche's Polivy can be prescribed at Big 5 hospitals
- by Eo, Yun-Ho Feb 16, 2022 05:51am
- The new lymphoma drug Polivy can be prescribed at the Big 5 General Hospital. According to related industries, Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, Seoul National University Hospital, and Antibody-drug conjugate (ADC) Polivy, which combines with existing BR therapy (Bendamustine & Rituximab) f
- Company
- GC Pharma & SK Bioscience are competing
- by Ji Yong Jun Feb 16, 2022 05:51am
- GC Pharma's Barycela challenges the international procurement market. Competition among domestic companies in the international procurement market for chickenpox virus vaccines is likely to begin in earnest. SK Bioscience seems to be challenging first while undergoing the World Health Organization (WHO) certification process for overseas sale
